Sangamo Therapeutics
SGMO
SGMO
134 hedge funds and large institutions have $61.3M invested in Sangamo Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 49 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
55% less capital invested
Capital invested by funds: $137M → $61.3M (-$76M)
65% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 26
Holders
134
Holding in Top 10
–
Calls
$91K
Puts
$81K
Top Buyers
| 1 | +$560K | |
| 2 | +$504K | |
| 3 | +$389K | |
| 4 |
Goldman Sachs
New York
|
+$303K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$177K |
Top Sellers
| 1 | -$907K | |
| 2 | -$864K | |
| 3 | -$596K | |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$465K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$442K |